Key result
Circulating natriuretic peptides (BNP/NT-pro-BNP) and cardiac troponin T (cTnT) serve as powerful prognostic biomarkers for predicting mortality and cardiovascular events in hemodialysis patients.
Why the study?
Do cardiac biomarkers (BNP, NT-pro-BNP, cTnT) predict mortality and improve treatment guidance in hemodialysis patients?
Do cardiac biomarkers (BNP, NT-pro-BNP, cTnT) predict mortality and improve treatment guidance in hemodialysis patients?
BNP, NT-pro-BNP, and cTnT are valuable biomarkers for predicting mortality and cardiovascular risk in hemodialysis patients, provided baseline levels are established to account for renal impairment.
Answers are grounded in this paper and cite their sources.
May aid risk stratification in hemodialysis; leaves open whether biomarker-guided therapy improves outcomes.
Circulating natriuretic peptides are useful biomarkers of left ventricular dysfunction and heart failure in the general population. Cardiac troponin T (cTnT) is also considered a sensitive marker of myocardial injury. However, the fact that levels of circulating natriuretic peptides and cTnT are almost invariably increased in end-stage renal disease patients has been considered a major limitation for their use as diagnostic or prognostic tools in this population. We provide an updated review on the role of natriuretic peptides and cTnT as biomarkers in predicting outcome and treatment in the hemodialysis population.
No takes yet. Share an insight, caveat, or question.
Angela Yee‐Moon Wang (2009) conducted a review in End-stage renal disease (ESRD) on hemodialysis. Natriuretic peptides (BNP/NT-pro-BNP) and cardiac troponin T (cTnT) was evaluated. Circulating natriuretic peptides (BNP/NT-pro-BNP) and cardiac troponin T (cTnT) serve as powerful prognostic biomarkers for predicting mortality and cardiovascular events in hemodialysis patients.
Synapse has enriched 10 related papers. Consider them for comparative context: